Clinical Trial of YYC301 for Treatment of Osteoarthritis of the Knee

Phase 2

Completed

• Conditions: Osteoarthritis, Knee
• Interventions: Drug: Celecoxib 200mg; Drug: Tramadol 150mg+ Celecoxib 200mg; Drug: Tramadol 37.5Mg+ Celecoxib 200mg; Drug: Tramadol 75mg+ Celecoxib 200mg

• Registration Number: NCT03850587
• Lead Sponsor: Yooyoung Pharmaceutical Co., Ltd.

Brief Summary

A Multi-center, Double-blinded, Randomized, Active-controlled, Parallel Design, phaseII Study to Investigate the Efficacy and Safety of YYC301 in Subject With Knee Osteoarthritis

Detailed Description

Not available

Study Timeline

• Study Start: 2018-08-30
• Study First Submitted: 2019-02-20
• Study First Submitted QC: 2019-02-20
• Study First Posted: 2019-02-22
• Primary Completion: 2020-05-12
• Study Completion: 2020-09-07
• Status Verified: 2021-05
• Last Update Submitted: 2021-05-07
• Last Update Posted: 2021-05-11

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 261

Inclusion Criteria

• Men/Women aged over 20

• Subjects who are diagnosed with one- or both-sided knee osteoarthritis according to the standards of clinical diagnosis from American College of Rheumatology(ACR)have knee osteoarthritis pain and meet over three of the following conditions.

  1. Older than 50
  2. Morning stiffness for less than 30 minutes
  3. Crepitus on active motion
  4. Bony tenderness
  5. Bony enlargement
  6. Not have heat-generating site

• Subjects who are diagnosed with degenerative osteoarthritis and have its pain at least for over 3 months before the screening visit.

• Subjects who are uncontrolled with pain after administration of Celecoxib at least for over 2 weeks before the randomization and have more than 40mm out of 100mm VAS at randomization.

• Subjects who voluntarily agree to participate in this clinical trial in writing.

Exclusion Criteria

• Subjects with rheumatoid arthritis or inflammatory, infectiousand metabolic arthritis.

• Subjects with ochronosis, hemochromatosis, secondary knee osteoarthritis by systemic disease.

• Subjects who have severe pain such as Sudek's atrophy, Paget's disease and spinal disc herniation.

• Subjects with poly-articular affected by severe pain of knee osteoarthritis.

• Subjects who take psychtrophic medicine and narcotic analgesics for over 3 months that might affect on pain sensory system.

• Subjects who had Tramadol but there was no improvement in pain.

• Subjects who got the follwing treatment and medicine before the screening;

  1. Subjects who had surgery on knee ligaments within a year, cartilage transplant and scarf osteotomy.
  2. Subjects who had arthroscopy within 6 months.
  3. Subjects with intra-articular knee joint steroid injection within 3 months.
  4. Subjects with HA injection in knee joint within 2 months.
  5. Subjects with systemic steroid injection within a month(but inhaled steroids)
  6. Subjects with knee replacement surgery.

• Subjects who hot the following treatment and medicine before the randomization;

  1. Subjects who had Celecoxib, acetaminophen or steroidal/non-steroidal anti-inflammatory drugs except low dose aspirin(before 300mg/day) But, acetaminophen and low dose aspirin (before 300mg/day) are prohibited within 24 hours)
  2. Nutritional supplements, physical therapy and Korean herbal medicine for knee osteoarthritis and it pain within 2 weeks.

• Subjects who have to take anticoagulant drugs such as warfarin and coumarin during this clinical trial.

• Subjects who took MAO inhibitors within 14 days before the screening or needed to take these drugs during this clinical trials.

• Subjects with drug and opioid hypersensitivity and who have history.

• Subjects with sulfanilamide allergy and who have history.

• Subjects with asthmma, acute rhinitis, nasal polyp, angioedema, urticaria, allergic reaction to aspirin or any oher NSAIDs(incluing COX-2 inhibitors)

• Subjects with significant investigations - Hyperkalemia(Exceeded 5.5mmol/L)

• Subjects with severe liver dysfunction (ALT or AST of more than 3.0 times the upper limit of ULN and 1.5 tmines the upper limit of ULN)

• Subjects with severe renal impairment (Serum Creatine > 3x ULN).

• Subjects with active peptic ulcer and gastrointestinal bleeding.

• Severe blood disease (Agranulocytosis, aplastic anemia, hemolytic anemia, Thrombocytopenia, etc.).

• Subjects with Crohn's disease or inflammatory bowel disease such as ulcerative clitis.

• Subjects with congestive heart failure(NYHA 2-4)

• Subjects with severe ischaemic heart disease, peripheral artery disease and/or cerebrovascular disease.

• Subjects with genetic problesa such as galactose intolerance), lapp lactase deficiency or glucose-galactose malabsorption).

• Subjects with acute alcohol intoxification.

• Subjects who are addicted with took central nervous system drugs such as painkillers, sleeping pills, anti-anxiety medications, etc.

• Subjects with severe bronchopulmonary dysplasia.

• Subjects with head injury history of brain structure lesions which may be in danger of mental confusion.

• Subjects with epilepsy who are treated properly.

• Subjects who use Tramadol to cure for narcotic withdrawal.

• Subjects who took other clinical drugs more than once within 30 days before the clinical trial.

• Subjects suspected to be pregnant who don't agree with the clinical method which is permitted medically during clinical trial(Method of hormone contraception, IUD(Intrauterine device) or IUS(Intrauterine system)), tubal ligation, bilateral tubal ligation(condom, Diaphragm, etc).

• Pregnant woman and breastfeeding woman.

• Subjects who can increase risk due to clinical test and administraion of drugs or have severe grade / chronic medical, mental condition or abnormal laboratory result that may interfere with the analysis of thest results.

• Any other ineligible condition at the direction of investigator that would be ineligible to participate the study.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
YYC301 placebo & Celecoxib	Celecoxib 200mg	Concomitant Drugs with Celecoxib 200mg and YYC301 one capsule.
YYC301-3 & Celocoxib placebo	Tramadol 150mg+ Celecoxib 200mg	YYC301-3 one capsule and Concomitant Drug Celocoxib placebo. \*YYC301-3 is a capsule. It is composed of Celocoxib 200mg and Tramadol 150mg complex)
YYC301-1 & Celocoxib placebo	Tramadol 37.5Mg+ Celecoxib 200mg	YYC301-1 one capsule and Concomitant Drug Celocoxib placebo. \*YYC301-1 is a capsule. It is composed of Celocoxib 200mg and Tramadol 37.5mg complex).
YYC301-2 & Celocoxib placebo	Tramadol 75mg+ Celecoxib 200mg	YYC301-2 one capsule and Concomitant Drug Celocoxib placebo. \*YYC301-2 is a capsule. It is composed of Celocoxib 200mg and Tramadol 75mg complex)

Primary Outcome Measures

Name	Time	Method
KOOS(Knee Injury and Osteoarthritis Outcome Score)	at 4,8,12 weeks after randomization after administration of YYC301(Experimental drug).	KOOS survey is consisted of total 42 questions at 5 groups. 7 questions about symptoms, 9 questions about pain, 17 questions about Function in daily,5 questions about function in sport and recreation(sport/Rec), 4 questions about the knee related quality of life(QoL). Subjects who are participated in this clinical trial, they directly assess these survey with 5 point Likert scale(0\~4, 0 means 'nothing' and 4 means 'most severe') and KOOS results are converted to WOMAC score.
100mm Pain VAS	at 1,4,8,12 weeks after randomization after administration of YYC301(Experimental drug).	Subjects who have severe pain at one-or both sided knee osteoarthritis directly assess the degree of pain (within 24 hours) with a straight line which has 0mm to 100mm. 0 mm means 'doesn't have pain' and 100 mm means 'maximum pain who can imagine'.In order to investigate the degree of subject's pain change from administration of YYC301(Experimental drug).
Patient Global Assessment(PGA)	at 4,8,12 weeks after randomization after administration of YYC301(Experimental drug).	Subjects who have been admistrated YYC301 have to directly perform the patient global assessment with 5 point Likert Scale. It has 0 to 5 scales. 0 means 'very poor' and 5 means' very good' In order to investigate the Patient Global point assessment at specific weeks.
Total dosage and dosage rate of rescue treatment.	at screening time(visit 1; 2 weeks before next visit 2), randomization(visit 2), 4, 8 weeks after randomization.	Subjects who administration of YYC301(Experimental drug) are investigated total dosage and dosage rate of rescue treatment.

Trial Locations

Locations (10)

Dong-A University Hospital.; 🇰🇷 Busan, Korea, Republic of

Bundang Seoul University Hospital; 🇰🇷 Seoul, Korea, Republic of

Gachon University Gil Medical Center; 🇰🇷 Seoul, Korea, Republic of

Gangnam Severance Hospital; 🇰🇷 Seoul, Korea, Republic of

Korea University Anam Hospital; 🇰🇷 Seoul, Korea, Republic of

Korea University Guro Hospital; 🇰🇷 Seoul, Korea, Republic of

Kyung Hee University Hospital at Gangdong; 🇰🇷 Seoul, Korea, Republic of

KyungHee University Medical Center; 🇰🇷 Seoul, Korea, Republic of

Soonchungyand University Hospital; 🇰🇷 Seoul, Korea, Republic of

The Catholic University of Korea, Seoul ST. Mary's Hospital.; 🇰🇷 Seoul, Korea, Republic of